Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

424.49 +4.60 (+1.10%)
Streaming Delayed Price Updated: 2:35 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
67 68 Next >
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
The first-in-class drug had suffered a setback in December. 
Via Investor's Business Daily
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)
 
Via Benzinga
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Is Vertex Pharmaceuticals Stock a Buy in 2025?
Via The Motley Fool
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
Via The Motley Fool
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Via The Motley Fool
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
How Is The Market Feeling About Vertex Pharmaceuticals?
 
Via Benzinga
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
 
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
 
Via Benzinga
3 Unstoppable Stocks to Buy in 2025
Via The Motley Fool
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease. 
Via Benzinga
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market. 
Via MarketBeat
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Via The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline. 
Via Benzinga
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Via The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2025
Via The Motley Fool
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up. 
Via Benzinga
Topics Artificial Intelligence
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months. 
Via Benzinga
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.